An assessment of massive-dose chemotherapy of malignant disease.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002455:Cell Division; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008558:Melphalan / Q000008:administration & dosage; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D013997:Time Factors; D014328:Trophoblastic Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D003561:Cytarabine; D014747:Vinblastine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D008558:Melphalan; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate